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Abstract
Background: The human papillomavirus (HPV) is the causative agent of cervical cancer, which is the leading
cancer-related cause of death for women in Sub-Saharan Africa. In 2013, the Gabonese Ministry of Health and the
Sylvia Bongo Ondimba Foundation implemented cervical cancer screening programs based on the detection of
cancerous lesions by visual inspection with acetic acid and/or Lugol’s iodine (VIA/VILI). This pilot study was set up
to determine the HPV profile and analyze the nucleotide sequence variation of HPV16 circulating in patients with
cervical abnormalities detected by VIA/VILI testing.
Methods: The cervical abnormalities observed upon VIA/VILI were confirmed by liquid-based cytology for all tested
women. Nested PCR using the MY09/11 and GP5+/6+ primer sets was used to detect HPVs present in the extracted
DNA. HPV genotypes were determined after sequencing of amplicons based on a high-throughput sequencing
approach. For isolates of the HPV16 genotype, the E6 gene and the long control region (LCR) were directly sequenced
using Sanger method.
Results: The study included 87 women who showed a positive VIA/VILI result. Cervical abnormalities were found in
40.23 % of women and 40 % were classified as high-grade lesions. The HPV detection rate was 82.9 % among women
with abnormal cytology. Among all the identified high-risk HPV genotypes, HPV16, 18 and 33 were the most frequent.
Multiple HPV infections were observed in 42.31 % of HPV-infected women. Analysis of the HPV16 sequence variation in
the E6 gene and in the LCR showed that 85.3 and 14.7 % belonged to the African and European lineages, respectively.
Among the African branch variants, Af2 was the most frequently identified in this study.
Conclusion: This study offers the first report of the HPV detection rate and molecular epidemiology among Gabonese
women with a positive result in a VIA/VILI screening test. Moreover, data on the HPV16 sequence variation confirm the
predominance of African variants in high-grade lesions.
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Background
In 2012, cervical cancer was the fourth most common
cancer in women worldwide, with 528,000 new diag-
nosed cases, of which 70 % were recorded in developing
countries [1]. Despite a global decrease, the incidence of
recorded cervical cancer in Africa increased from 80,419
cases in 2008 to 99,038 cases in 2012. However, these
statistics may be largely underestimated because only
8 % of the population in Sub-Saharan Africa is covered
by cancer registries [2]. Moreover, in Sub-Saharan
Africa, about one out of every two women who are diag-
nosed with cervical cancer will die of this disease [1, 3].
Cytology-based screening has considerably reduced
the incidence of cervical cancer in countries that have
implemented national programs. In Sub-Saharan Africa,
these programs are difficult to organize due to limited
infrastructures and funding, lack of trained staff, and a
very strong competition with other national disease con-
trol programs, such as HIV, tuberculosis or malaria, and
the fight against infant mortality. To overcome these is-
sues and ensure early detection, cervical cancer screen-
ing programs based on visual inspection with acetic acid
and Lugol’s iodine (VIA/VILI) can provide an immediate
diagnostic evaluation [4]. Although the specificity of
VIA/VILI seems to be lower in comparison with the Pap
smear test, both tests have similar sensitivity [5]. VIA/
VILI has the potential to become a very useful screening
tool in developing countries even if it may be not
adequate for primary screening [6].
The human papillomavirus (HPV) genotypes most fre-
quently indicated as the causal factor of cervical cancer
are HPV16, 18, 31, 33, 35, 45, 52 and 58 [7]. In Sub-
Saharan Africa, the distribution of HPV genotypes in
women remains under-documented. However, recent
studies have shown that HPV16, 18 and 45 and HPV16
and 35 are the most frequent genotypes in West Africa
and in South Africa, respectively [8, 9]. In Central
Africa, the distribution of HPV genotypes among cer-
vical cancer patients is available for some countries. In
Gabon, the reported age-standardized incidence and
mortality rates of cervical cancer were 19.9 and 8.4 per
100,000 women in 2014 [10]. A previous study of
women either attending an antenatal clinic or presenting
general symptoms related to genital diseases at a hos-
pital revealed a high prevalence of HPV (46 %) in
Libreville. The most frequent HPV genotypes then
described were HPV16, 53 and 58 with 10, 12 and 11 %
of prevalence, respectively [11]. In another study, the
analysis of 39 HPV16 variants from patients with pre-
cancerous lesions and invasive or micro-invasive carcin-
omas revealed the presence of only two African variants:
Af1 (68 %) and Af2 (32 %) [12].
In January 2013, the Gabonese Ministry of Health,
with the support of the Sylvia Bongo Ondimba Founda-
tion, implemented cervical cancer screening programs at
the Institut de Cancérologie de Libreville (ICL) and the
Centre Hospitalier Universitaire de Libreville (CHUL).
The cervical screening program is based on the detec-
tion of cancerous lesions and/or cervical abnormalities
by VIA/VILI. Based on the World Health Organization
(WHO) guidelines on “cervical cancer screening and
treatment of precancerous lesions”, which recommends
HPV detection, this pilot study was included in an
epidemiologic surveillance program initially aimed to
determine the detection rate and distribution of HPV
genotypes among women with cervical abnormalities
revealed by VIA/VILI testing [13]. We also analyzed the
nucleotide variations in the E6 gene and the long control
region (LCR) to identify the different HPV16 variants




This multi-center and cross-sectional study was carried
out at two hospital centers, the ICL and the CHUL,
located in Libreville (Gabon) which are screening refer-
ence centers for cervical and breast cancers. This screen-
ing program was open to women aged 25 and older. A
total of 960 women residing in a suburb of Libreville
participated in a screening program between January
and March 2014. Only women whose VIA/VILI test re-
sults indicated cervical abnormalities during this period
were included and signed specific informed consent
forms that authorized the use of their cervical samples
collected during a routine screening process. A general
physical and detailed gynecological examination was
carried out followed by VIA/VILI, screening with liquid-
based cytology (LBC) and HPV testing. Exclusion
criteria were pregnancy, severe gynecological bleeding
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and previous hysterectomy. The study was approved by the
Medical Ethics Committee of Gabon (consent number
PROT no. 0010/2013/SG/CNE), obtained the authorization
of the Gabonese Ministry of Health (no. 00775/MS/
CAB.M/SG/DGS) and of the Scientific Committee of the
Centre International de Recherches Médicales de Franceville
(CIRMF).
Sample collection
The cervix was inspected after application of acetic
acid and Lugol’s iodine according to the International
Agency for Research on Cancer (IARC) criteria [14].
After a few minutes, exfoliated cells of the uterine
ecto- and endocervix were collected by scraping with
a cytobrush and then conserved in a Thin-Prep solu-
tion for LBC and HPV analyses. LBC samples were
screened at Biomnis laboratory according to the Be-
thesda system 2001 and categorized as negative for
intraepithelial lesions or malignancy (normal), atyp-
ical squamous cells of undetermined significance
(ASC-US), low-grade squamous intraepithelial lesions
(LSIL), high-grade squamous intraepithelial lesions
(HSIL) and carcinoma.
DNA extraction
A portion of Thin-Prep LBC samples were stored at
-80 °C until the total genomic DNA extraction using the
DNeasy Blood and Tissue kit (Qiagen, CA, USA) ac-
cording to the manufacturer’s instructions. Extracted
DNA was stored at -20 °C until subsequent analyses.
DNA was quantified using Qubit® dsDNA BR Assay kit
with the Qubit 2.0 fluorimeter (Life Technologies, CA,
USA).
L1 gene amplification for sequencing
The nested PCR assay was performed using two sets of
degenerate primers (MY09/11 and GP5+/6+) (Additional
file 1: Table S1). The first reaction was performed in
50 μl using 5 μl of template DNA, 1X PCR buffer (Invi-
trogen, CA, USA), 2.5 mM MgCl2, 0.125 μM of each
deoxynucleotide triphosphate (dNTP), 0.25 μM of each
consensus primer MY09/MY11 and 5 U of Taq DNA
polymerase (Invitrogen). Thermal cycling performed
with the following program: 10 min at 95 °C, 40 cycles
of 45 s at 95 °C, 45 s at 55 °C and 40 s at 72 °C, with a
final extension step at 72 °C for 8 min.
The second reaction was also performed in 50 μl in-
cluding 5 μl of amplified DNA, 1X PCR buffer, 1.5 mM
MgCl2, 0.05 μM each dNTP, 5 U Taq DNA polymerase
and 0.4 μM each consensus primer GP5+/6+ tagged
with an Illumina adapter sequence. Thermal cycling
used the following program: 5 min at 94 °C, 40 cycles of
30 s at 94 °C, 30 s at 50 °C and 1 min at 72 °C, with a
final extension step at 72 °C for 5 min. All primer
sequences used are listed in Additional file 1: Table S1.
The amplicon libraries and sequencing process are
described in Supplementary Data.
Generation of amplicon libraries
E-GP5+/6+ amplicons for sequencing were generated by
PCR using modified primer sets, E-GP5+ and E-GP6+
(Additional file 1: Table S1). They were purified using
magnetic beads (Agencourt® Ampure® XP) and indexed
by PCR using the Nextera XT Index kit (Illumina, CA,
USA) according to the manufacturer’s instructions. The
resulting amplicon libraries were quantified using a
Qubit fluorimeter with Qubit dsDNA HS Assay kit (Life
Biotechnologies) and then with SYBR green quantitative
PCR (Kapa Biosystems). Libraries were then normalized
and multiplexed, resulting in a pool of libraries at a final
concentration of 4 pM that was then mixed with a 4 pM
PhiX control library. After a final heat-denaturation step
(2 min at 96 °C), 600 ul of the pooled amplicon libraries
were loaded into a MiSeq V2 Reagent v2 (300 cycles)
cartridge (Illumina).
Bioinformatics analyses for HPV genotyping
HPV genotypes were identified by running a python
script on the reads. At the beginning, all paired-end
reads were trimmed, filtered according to their quality
and merged at the end. All merged reads were mapped
against a local HPV database built from all viral se-
quences found in GenBank (NCBI-GenBank Flat File
Release 191.0). To remove any risk of contamination
among samples, all determined HPV genotypes repre-
sented by less than 2 % of the total number of reads in a
sample were discarded. An HPV genotype was consid-
ered correctly identified if, among all reads related to the
considered genotype, at least one read had a value of
around 0 % of divergence. To validate a representative
group of reads related to one specific HPV genotype, the
distribution of the divergence percentage (DP) was de-
termined based on the mean and the median of DPs of
each HPV genotype as indicated in Additional file 1:
Table S2.
Sequence analysis of the E6 gene and LCR of HPV16
For HPV16-positive samples, the HPV E6 and LCR open
reading frames were amplified by PCR as described in
Yamada et al. [15]. Thermal cycling was based on the
following program: 5 min at 95 °C, 40 cycles of 60 s at
95 °C, 60 s at 55 °C and 60 s (90 s for LCR) at 72 °C,
with a final extension step at 72 °C for 5 min. The PCR
mix contained 10 mM Tris (pH 8.3), 200 μM of each
dNTP, 4 mM MgCl2, 0.125 μM of each sense-strand and
anti-sense strand oligonucleotide primers, and 2.5 U of
Taq in a final volume of 100 μl. All PCR products were
sequenced using the BigDye Terminator v3.1 Cycle
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Sequencing kit (Applied Biosystems, ville?, pays?) ac-
cording to the manufacturer’s protocol. The full length
E6 and LCR ORFs were aligned with the reference
HPV16 sequence (GenBank accession number: K02718)
using multiple sequence alignment of the MEGA 5.2
package in the Clustal W program. The taxonomic
nomenclature of molecular variants used in this study
was adapted from Huertas-Salgado et al. [16].
Statistical analysis
Statistical analyses were performed using IBM SPSS
version 20.0.0. Summary statistics for age at study entry
(n, mean, standard error, median, minimum and max-
imum) and cervical lesions (n, proportion) were pro-
duced. The associations between HPV infection and age
groups and severity of cytological lesions were tested
using the chi-squared test at the 95 % confidence level.
Nucleotide sequence accession numbers
The E6 and LCR sequences are available in the DDBJ/




Among the 960 women participating in this screening
program, only 93 showed positive VIA/VILI tests and
were eligible. Six samples were excluded due to incon-
clusive cytological tests. Ultimately, 87 women were in-
cluded in this study. The population was aged 24 to 80,
the mean age of the cohort was 47.06 years (SD ±
12 years). LBC tests showed that 59.77 % (52/87) had
normal cytology (Table 1). Among women with ab-
normal cytology, 20 % (7/35) had cervical cancer,
20 % (7/35) had HSIL, 22.9 % (8/35) had LSIL and
37.14 % (13/35) had ASC-US.
HPV distribution among normal and dysplastic lesions
Nested PCR detected HPV DNA in 59.77 % (52/87) (CI:
49.5–70.1) of women. The mean age of women with
positive HPV DNA was 48 (SD ± 12) years and 46.15 %
(24/52) of women were aged 50–80. The association
between HPV infection and abnormal cytology was
significant (p ˂ 0.01) and increased with the severity of
the cervical lesions (p < 0.01) (Table 1). Likewise, a sig-
nificant difference was observed in the HPV infection
rate among the three age groups (p ˂ 0.05) (Table 1).
The HPV infection profile was determined by high-
throughput sequencing of GP5+/6+ amplicons. All
detected HPV genotypes were classified into two cat-
egories: high-risk (HR) of cervical cancer (HPV16, 18,
31, 33, 35, 45 and 58) and low-risk (LR) of cervical can-
cer (HPV32, 62, 72, 81, 87 and 90). The detection rate of
all HR-HPV was 94.64 % with a predominance of
HPV16 (76.92 %), followed by HPV33 (2 5 %) and
HPV18 (21.15 %). In total, 57.69 % (30/52) of cases that
tested positive for HPV DNA contained a single HPV
genotype (Table 2). HPV DNA was detected in 80 % of
women with abnormal cytology. HPV16 was the most
prevalent genotype reported in women with high-grade
lesions: all HSIL (14) were infected by HR-HPV, among
which 85.7 % HPV16 (12/14) and 14.3 % HPV18 (2/14)
were found alone or in co-infection with other HPVs.
HPV16 was detected alone in 42.86 % and 60 % of HSIL
and carcinoma cases, respectively, whereas HPV18 was
detected in a single infection in only one case of HSIL
(1/7). All co-infections detected in HSIL cases involved







[24–42] 34 (39.08) 8 (23.53) < 0.05a
[43–61] 47 (54.02) 24 (51.06)
[62–80] 6 (6.90) 3 (50)
Cytology result
Normal cytology 52 (59.77) 24 (46.15) < 0.01b
Abnormal cytology 35 (40.23) 28 (82.9)
ASC-US 13 (37.14) 7 (53.84)
LSIL 8 (22.86) 7 (87.50)
HSIL 7 (20) 7 (100)
Carcinoma 7 (20) 7 (100)
aChi-squared = 6.47; df = 2
bChi-squared = 36.00; df = 1
Table 2 HPV prevalence and type distribution (N = 87a)
HPV type nb (%) Single infection Multiple infections
HPV-positive 52 (59.77) 30 (57.69) 22 (42.31)
High-risk (HR-HPV)
HPV16 40 (76.92) 19 (47.5) 21 (52.5)
HPV18 11 (21.15) 4 (36.36) 7 (63.64)
HPV31 1 (1.78) 0 1 (100)
HPV33 13 (25.00) 2 (50) 9 (69.23)
HPV35 2 (3.57) 1 (50) 1 (50)
HPV45 7 (12.5) 0 7 (100)
HPV58 6 (10.71) 1 (16.67) 5 (83.33)
Low-risk (LR-HPV)
HPV32 2 (3.85) 1 (50) 1 (50)
HPV62 1 (1.78) 0 1 (100)
HPV72 9 (17.31) 1 (11.10) 8 (88.90)
HPV81 1 (1.78) 0 1 (100)
HPV90 1 (1.78) 1 (100) 0
HPV87 1 (1.78) 0 1 (100)
aNumber of tested cervical samples
bNumber of subjects in a given category
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HPV16 (75 %) (3/4) or HPV18 (25 %) (1/4). Only one
case of triple infection with HPV16, HPV18 and HPV45
was detected in HSIL-positive samples.
Regardless of the cytological result, 50 % of HPV16-
positive, 69.23 % of HPV18-positive and 86.6 7 % of
HPV33-positive women were co-infected with at least
one other HR- and/or LR-HPV type. HR-HPVs and LR-
HPVs were in co-infection with more than one other
HPV in 43.4 % and 88.5 % of cases, respectively. The
detection rate of LR-HPV was 2.29 % with two main
genotypes (HPV72 and HPV32). All other LR-HPV
genotypes (32, 81, 87 and 90) were detected only once
singly or in co-infection with other HPVs (Table 2).
HPV90 was detected in single infection in LSIL samples,
whereas the three other cases of LSIL were infected by
HPV33, including one with a multi-infection by HPV16
and HPV58.
Characterization of the E6/LCR sequence in HPV16
The E6 and LCR regions of the HPV16 genome were amp-
lified and sequenced for 11 of the 22 detected HPV16
cases. Nucleotide (nt) changes were analyzed from nt 104
to 559 for the E6 gene and from nt 7384 to 7835 for the
LCR sequence (Table 3). A comparison with the reference
HPV16 sequence (GenBank accession number: K02718)
showed that all sequences (E6 and LCR) contained at least
one specific nucleotide variation. Fourteen nucleotide vari-
ations were found in the E6 region: nine non-synonymous
mutations (G132C (R10T), G132T (R10I), C143G (Q14D),
G145T (C51F), G255T (D64E), C256T (H78Y), T295G
(L83V), C335T (H78Y) and T350G (L83V)) and five syn-
onymous (silent) mutations (T109C, G196A, T286A,
A289G and A403G). The non-synonymous mutations
C143G, G145T, C335T and G132C/T that lead to Q14D
and H78Y were the most frequent mutations (81.8 %)
followed by the mutations R10T (54.5 %) and R10I
(18.2 %), which are specific to African variants. Additional
mutations (G196A, G255T, C256T, and T295G) inducing
an amino-acid change (D64E) were all detected in only one
sample. In addition, two samples showed a T-to-G muta-
tion at position 350, specific to the European lineage.
Similarly, the LCR showed 15 nucleotide variations
in eight samples. All eight samples showed the same
mutation at six different sites: G7489A, G7520A,
C7688A, C7763T, C7785T and G7833T. Six samples
(75 %) shared the C7668T mutation, and five samples
(62.5 %) contained the A7484C or G7825A mutations.
The T7713A, C7417T and A7787T mutations were
found in two samples each. All variation analyses
based on the combination of the E6 gene and the
LCR revealed that 85.7 % (12/14) and 14.7 % (2/14)
belonged to the African and European branches, re-
spectively. Af1 and Af2 were the most frequently
identified variants with 33.3 % (3/9) and 55.6 % (5/9)
in HSIL samples, respectively, and in equal propor-
tion (40 % for each variant) in samples cytologically
identified as carcinoma. Both European variants iden-
tified belonged to the G350 class.
Table 3 Nucleotide sequence variation in the E6 and LCR regions in HPV16 isolates
E6 nucleotide position
Nucleotide position 109 132 143 145 196 255 256 286 289 295 335 350 403
Predicted amino acid
substitution
2 F R10I/R10T Q14D V31 C51F A61 V62 D64E H78Y L83V L100
K02718 T G C G G G C T A T C T A
CHUA130001 - - - - - - - - - - G
CHUA130002
CHUA 130003
CHUA 130012 - - - - - - - - - - G
CHUA 130026 - C G T - - - a g - T -
CHUA 130035 - C G T - - - a g - T - -
CHUA 130021 c T G T - - a g - T - g
CHUA 130024 c T G T - - - a g - T - g
CHUA 140002 c T G T - - - a g - T - g
CHUA140010 c T G T - - - a g T - g
CHUL140009 c T G T - - - a g T - g
CHUL140002 c T G T - - - a g T - g
CHUL140016
CHUA 130025 - - G T a T T a g G T - -
(-): insufficient sequence to determine the class
Moussavou et al. Infectious Agents and Cancer  (2016) 11:50 Page 5 of 9
Discussion
This study reports the detection rate and the genotype-
specific distribution of HPV among 87 women living in
Libreville, Gabon presenting suspicious cervical abnor-
malities after a positive VIA/VILI test. These cervical
abnormalities were confirmed by LBC in 40.23 % of
cases, of which 40 % were HSIL. HPV DNA was
detected in 59.77 % of the samples, with three main
genotypes: HPV16, 18 and 33.
Detection rate of HPV
Due to the difficulties in implementing cervical
cytology-based screenings in developing or in low-
income countries, VIA/VILI is particularly recom-
mended for the early detection of cervical neoplasia [17].
Several studies have suggested that the specificity of VIA
and Pap smear tests for early detection of CC are similar
[5]. However, multiple parameters may affect VIA/VILI
test accuracy from one health center to another, includ-
ing lack of standardized protocols, differences in training
of the health-care staff, lack of uniformity in application
of gold standards for disease definition, and, finally, the
absence of blind readings [6, 18]. Ultimately, inadequate
conditions for one or several parameter(s) can give false-
positive results. In our study only 40.23 % of positive
VIA/VILI cases were confirmed by LBC. As noted in the
literature, our data confirm the need to combine the
VIA/VILI screening test with other histological/cyto-
logical and/or molecular assays such as HR-HPV testing.
In fact, the predicted positive value of VIA is poor and
needs triaging, such as HPV testing to improve the
screening results — as observed in India [19] —, or
histological screening as indicated by Mpiga et al., in
Gabon [20].
The high detection rate of HPV (59.77 %) in this study
among Gabonese women with cervical abnormalities
was similar to those reported in previous studies con-
ducted in Libreville [21] and in Bioko, Equatorial Guinea
[22], which both found a prevalence of 60 %. However,
another study conducted in Libreville among women at-
tending an antenatal check-up or presenting general
genital symptoms revealed a lower HPV prevalence rate
(46 %) [11]. The difference in HPV prevalence between
studies can be attributed to the study population and the
laboratory methods used. Moreover, the HPV detection
rate increases with the severity of cytological abnormal-
ities: HPV was found in 100 % of HSIL samples. How-
ever, in most geographical regions, a peak of HPV
prevalence is observed in women aged ≤ 25, followed by
a decrease in older age groups. In our study, as expected
in Africa and South America [23], an increased and
stable HPV infection prevalence was observed among
women aged 45 and older.
As observed in Equatorial Guinea and Gabon [21, 22],
the most frequent HPV genotypes were HPV16, 18 and
33, in women presenting invasive cervical cancer,
whereas HPV16, 18, 35, 56 and 82 were the genotypes
most frequently found in Cameroon [24]. This difference
may be partly attributable to the methods of HPV detec-
tion used. HPV detection methods vary in sensitivity
Table 3 Nucleotide sequence variation in the E6 and LCR regions in HPV16 isolates (Continued)
LCR nucleotide position
Nucleotide position 7386 7393 7417 7435 7484 7489 7520 7668 7688 7713 7763 7785 7787 7825 7833 Variant Class Cytology
Predicted amino acid
substitution
K02718 G C T G A G G C C T C C A G G
CHUA130001 E G350 LSIL
CHUA130002 - - - A C A A T A - T T - A T Af 2 - ASC-US
CHUA 130003 - - - A C A A T A - T T - A T Af 2 - HSIL
CHUA 130012 E G350 carcinoma
CHUA 130026 Af 1 1a Normal
CHUA 130035 - - - - - A A - A A T T - - T Af 1 1a HSIL
CHUA 130021 Af 2 a carcinoma
CHUA 130024 Af 2 a ASC-US
CHUA 140002 C - - - C A A T A - T T - A T Af 2 a carcinoma
CHUA140010 C - - A C A A T A - T T - A T Af 2 - Normal
CHUL140009 Af 2 a HSIL
CHUL140002 C - - A C A A T A - T T - A T Af 2 a HSIL
CHUL140016 - T - - - A A - A A T T - - T Af 1 - carcinoma
CHUA 130025 - - C - - A A T A - T T T - T Af 1 - carcinoma
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according to the types of material, anatomical location,
sets of primers used and the study population [25, 26].
In addition to the main HR-HPV genotypes detected,
only one case of HPV90 was observed in LSIL. This has
already been reported in a previous study on women in
the USA [27]. Molecular investigation of this genotype
based on the E6 gene showed a K16N mutation involved
in p53 degradation that may explain its oncogenic
potential in patients with negative Papanicolaou test [28].
Analysis of the E6/LCR sequences in HPV16
The analysis of the nucleotide variation in the HPV se-
quence distinguished among HPV sub-types and can be
used for epidemiological and transmission studies [29].
Villa et al. suggested that the distribution of HPV geno-
types is associated with the ethnic group and geography
[30]. Viral persistence and progression towards cervical
cancer may be enhanced in HPV16 variants, which may
partly explain the difference in prevalence in some pop-
ulations [29]. Previous studies in Gabon and in other
Sub-Saharan African countries have shown the predom-
inance of the African lineage in HSIL cases [12, 31–34].
However, our analysis of the nucleotide variation of all
HPV16 sequences showed that 85.7 % of the sequences
belonged to the African branch (Af1 and Af2) and
14.3 % to the European branch. This European lineage
in a HSIL+ case was identified for the first time in
Gabon, whereas these non-African lineages have already
been reported in northern and southern Africa. The
introduction of this European lineage may be due to
contacts between European and African populations.
However, a larger female cohort is needed to test this
hypothesis. All the mutations in the E6 and LCR
sequences found in our study, such as the amino-acid
substitutions Q14D, C51F, D64E and H78Y, which
reduce intracellular binding to E6AP and degradation of
the cellular tumor antigen p53, have already been
described [16, 35–37]. Moreover, the nucleotide varia-
tions observed in the LCR sequence are known binding
sites for various transcription factors, such as YY1, AP1,
Oct-1 [38]. The G7520A mutation located at the YY1
binding site has been described in each cervical cancer
patient worldwide [36] and is involved in the repression
of HPV transcription and in quenching AP1 activity. We
observed this nucleotide variation in all cases of carcin-
oma, but also in two women with normal cytology results.
A larger number of HPV16 sequences including other
sequences or the complete genome would help to better
identify the full panel of nucleotide variation and to de-
termine their association with cervical lesions. Overall,
our results are in agreement with the current data in the
literature and confirm the importance of considering the
African lineage. These molecular data of the E6 gene
and the LCR region could be completed with those of
the L1 gene. Indeed, Pande et al., showed that the
A6695C mutation, which induces the replacement of
threonine (polar uncharged) by proline (unpolar ali-
phatic), affected the structure or function of the L1 gene.
This modification at the amino acid level may play an
important role in immune recognition and vaccine
development strategies [36].
Limitations and strengths
The main limitation of this study was the small number
of women included that limits the generalization of our
data to the whole Gabonese and/or Central African pop-
ulations. Furthermore, information on patient character-
istics was not available for each participant, risk factors
such as age at first intercourse or the number of sexual
partners were not analyzed. Despite these limitations,
this study shows the necessity to implement co-testing
(VIA/L associated to HPV assay) in low-income coun-
tries, which could be considered an interesting alterna-
tive to VIA-cytology, currently used in Gabon.
Conclusions
This study provides the first data on the HPV detection rate
and molecular epidemiology among Gabonese women with
a positive VIA/VILI test and cervical abnormalities con-
firmed by cytological analysis. HPV16, HPV18 and HPV33
were the most frequent genotypes found among these
women. Furthermore, the analysis of HPV16 sequence vari-
ation in the E6 and LCR regions of the genome illustrate
the predominance of the African variants in HSIL cases.
Additional file
Additional file 1: Table S1. List of PCR primers sequences used.
Table S2. Identified HPV genotypes per samples. (DOCX 287 kb)
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